133 related articles for article (PubMed ID: 27076131)
1. Generation of a Single-Cycle Replicable Rift Valley Fever Vaccine.
Murakami S; Terasaki K; Makino S
Methods Mol Biol; 2016; 1403():187-206. PubMed ID: 27076131
[TBL] [Abstract][Full Text] [Related]
2. Development of a novel, single-cycle replicable rift valley Fever vaccine.
Murakami S; Terasaki K; Ramirez SI; Morrill JC; Makino S
PLoS Negl Trop Dis; 2014 Mar; 8(3):e2746. PubMed ID: 24651859
[TBL] [Abstract][Full Text] [Related]
3. A single-cycle replicable Rift Valley fever phlebovirus vaccine carrying a mutated NSs confers full protection from lethal challenge in mice.
Terasaki K; Juelich TL; Smith JK; Kalveram B; Perez DD; Freiberg AN; Makino S
Sci Rep; 2018 Nov; 8(1):17097. PubMed ID: 30459418
[TBL] [Abstract][Full Text] [Related]
4. Attenuation of pathogenic Rift Valley fever virus strain through the chimeric S-segment encoding sandfly fever phlebovirus NSs or a dominant-negative PKR.
Nishiyama S; Slack OA; Lokugamage N; Hill TE; Juelich TL; Zhang L; Smith JK; Perez D; Gong B; Freiberg AN; Ikegami T
Virulence; 2016 Nov; 7(8):871-881. PubMed ID: 27248570
[TBL] [Abstract][Full Text] [Related]
5. Rift Valley Fever Virus MP-12 Vaccine Is Fully Attenuated by a Combination of Partial Attenuations in the S, M, and L Segments.
Ikegami T; Hill TE; Smith JK; Zhang L; Juelich TL; Gong B; Slack OA; Ly HJ; Lokugamage N; Freiberg AN
J Virol; 2015 Jul; 89(14):7262-76. PubMed ID: 25948740
[TBL] [Abstract][Full Text] [Related]
6. Single-cycle replicable Rift Valley fever virus mutants as safe vaccine candidates.
Terasaki K; Tercero BR; Makino S
Virus Res; 2016 May; 216():55-65. PubMed ID: 26022573
[TBL] [Abstract][Full Text] [Related]
7. Rescue of infectious rift valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene.
Ikegami T; Won S; Peters CJ; Makino S
J Virol; 2006 Mar; 80(6):2933-40. PubMed ID: 16501102
[TBL] [Abstract][Full Text] [Related]
8. The L, M, and S Segments of Rift Valley Fever Virus MP-12 Vaccine Independently Contribute to a Temperature-Sensitive Phenotype.
Nishiyama S; Lokugamage N; Ikegami T
J Virol; 2016 Jan; 90(7):3735-44. PubMed ID: 26819307
[TBL] [Abstract][Full Text] [Related]
9. Attenuation and protective efficacy of Rift Valley fever phlebovirus rMP12-GM50 strain.
Ly HJ; Nishiyama S; Lokugamage N; Smith JK; Zhang L; Perez D; Juelich TL; Freiberg AN; Ikegami T
Vaccine; 2017 Dec; 35(48 Pt B):6634-6642. PubMed ID: 29061350
[TBL] [Abstract][Full Text] [Related]
10. Using reverse genetics to manipulate the NSs gene of the Rift Valley fever virus MP-12 strain to improve vaccine safety and efficacy.
Kalveram B; Lihoradova O; Indran SV; Ikegami T
J Vis Exp; 2011 Nov; (57):e3400. PubMed ID: 22083261
[TBL] [Abstract][Full Text] [Related]
11. Rift Valley fever virus MP-12 vaccine encoding Toscana virus NSs retains neuroinvasiveness in mice.
Indran SV; Lihoradova OA; Phoenix I; Lokugamage N; Kalveram B; Head JA; Tigabu B; Smith JK; Zhang L; Juelich TL; Gong B; Freiberg AN; Ikegami T
J Gen Virol; 2013 Jul; 94(Pt 7):1441-1450. PubMed ID: 23515022
[TBL] [Abstract][Full Text] [Related]
12. Risk analysis of inter-species reassortment through a Rift Valley fever phlebovirus MP-12 vaccine strain.
Ly HJ; Lokugamage N; Nishiyama S; Ikegami T
PLoS One; 2017; 12(9):e0185194. PubMed ID: 28926632
[TBL] [Abstract][Full Text] [Related]
13. Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate.
Ikegami T
Expert Rev Vaccines; 2017 Jun; 16(6):601-611. PubMed ID: 28425834
[TBL] [Abstract][Full Text] [Related]
14. The dominant-negative inhibition of double-stranded RNA-dependent protein kinase PKR increases the efficacy of Rift Valley fever virus MP-12 vaccine.
Lihoradova O; Kalveram B; Indran SV; Lokugamage N; Juelich TL; Hill TE; Tseng CT; Gong B; Fukushi S; Morikawa S; Freiberg AN; Ikegami T
J Virol; 2012 Jul; 86(14):7650-61. PubMed ID: 22573861
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of Rift Valley fever MP-12 and arMP-12ΔNSm21/384 vaccine candidates in goats (Capra aegagrus hircus) from Tanzania.
Nyundo S; Adamson E; Rowland J; Palermo PM; Matiko M; Bettinger GE; Wambura P; Morrill JC; Watts DM
Onderstepoort J Vet Res; 2019 Jan; 86(1):e1-e8. PubMed ID: 30843406
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a recombinant Rift Valley fever virus MP-12 with NSm deletion as a vaccine candidate in sheep.
Weingartl HM; Nfon CK; Zhang S; Marszal P; Wilson WC; Morrill JC; Bettinger GE; Peters CJ
Vaccine; 2014 Apr; 32(20):2345-9. PubMed ID: 24462482
[TBL] [Abstract][Full Text] [Related]
17. Post-exposure vaccination with MP-12 lacking NSs protects mice against lethal Rift Valley fever virus challenge.
Gowen BB; Bailey KW; Scharton D; Vest Z; Westover JB; Skirpstunas R; Ikegami T
Antiviral Res; 2013 May; 98(2):135-43. PubMed ID: 23523764
[TBL] [Abstract][Full Text] [Related]
18. Rift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolates.
Pittman PR; Norris SL; Brown ES; Ranadive MV; Schibly BA; Bettinger GE; Lokugamage N; Korman L; Morrill JC; Peters CJ
Vaccine; 2016 Jan; 34(4):523-530. PubMed ID: 26706271
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy of two next-generation Rift Valley fever vaccines.
Kortekaas J; Oreshkova N; van Keulen L; Kant J; Bosch BJ; Bouloy M; Moulin V; Goovaerts D; Moormann RJ
Vaccine; 2014 Sep; 32(39):4901-8. PubMed ID: 25050973
[TBL] [Abstract][Full Text] [Related]
20. [Study on DNA immune of envelope protein gene of Rift Valley Fever Virus].
Wang QH; Wang XJ; Hu S; Ge JY; Bu ZG
Wei Sheng Wu Xue Bao; 2007 Aug; 47(4):677-81. PubMed ID: 17944371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
